

2024

Employee Benefits Market Outlook



This material is for informational purposes and is not intended to be exhaustive nor should any discussions or opinions be construed as legal advice. Contact your broker for insurance advice, tax professional for tax advice, or legal counsel for legal advice regarding your particular situation. USI is not responsible for the content of the information provided or for consequences of any actions taken based on the information provided. © 2024 USI Insurance Services. All rights reserved.



Table of Contents

Executive Summary
Is Covering GLP-1s Worth the Cost? Evaluate the clinical value of GLP-1 treatments against the cost when deciding to include coverage for plan members.
3 Prescription Drug Trends Impacting Employer Pharmacy Spending
The Hidden Cost of Employees Struggling With Well-Being
SECURE 2.0 Act Helps Employers Increase Retirement Readiness and Reduce Costs
Market Trends Impact Salary Decisions for 2024 and Beyond
Unlock the Savings Advantage With a Stop-Loss Captive
Proposed Rule May Impact the Future of Fixed Indemnity Products
Reduce the Risk of Noncompliance With Leave Management Support

Executive Summary

As the U.S. economy continues its turbulent path toward a soft landing, employers are generally seeing a reduction in unemployment and turnover. Unfortunately, employers will face increased pressure from the employee benefits expense line, which will be fraught with challenges over the next 12 to 24 months.

- Expensive treatments, including new and emerging cell and gene therapies, GLP-1s and the usual array of specialty drugs will outpace their usual significant impact on total claims.
- Mental health claims, whether paid for by the plan or not, continue to impact many employers' finances and productivity.
- Premiums are increasing due to staffing shortages and higher labor costs, and hospitals have more negotiating power as a result of consolidation.

Medical Benefits — Healthcare costs continue to go up, driven by medical inflation and increasing demand for high-cost medications and treatments.



Total medical spend for Type 2 diabetes increased 20.7% from \$16,935 per member per year in 2020 to \$20,432 in 2023, driven by a 115% increase in spending on high-cost GLP-1 medications. Several gene and cell therapies currently available cost \$850,000 or more per dose. As more therapies are approved every year, the likelihood of experiencing a high-cost claim increases.

Employee Well-Being — Financial stress is taking a toll on employees' physical and emotional wellness and productivity.



Nearly half (48%) of employees cite financial concerns as the cause of lower mental health, up from 31% in 2022. Twenty-three percent of employees state financial stress impacts their ability to focus and be productive at work. Employees with financial stress are also twice as likely to look for a new job.

Employee Pay — Continued low unemployment and growing wage transparency will make it difficult for employers to offer competitive benefits that meet employee needs and expectations.



Employers plan to provide competitive base salary increases in 2024 and expect a 3% to 4.5% budget increase for pay. Growing legislative interest in pay equity and transparency is putting more pressure on employers to be upfront about wages, which could impact employee satisfaction and turnover.

A strategic approach to benefits planning and spending helps employers make decisions that contribute to employee satisfaction and business growth. In USI Insurance Services' 2024 Employee Benefits Market Outlook, our benefits and compliance experts help employers identify top cost drivers, analyze the potential financial impact and provide recommendations based on the proven success of hundreds of thousands of clients.



Arthur Hall Employee Benefits National Practice Leader